ArticleAnnals of the American Thoracic Society2026
Real-world generalizability of sleep apnea-related polysomnographic metrics and their associations with clinical comorbidities.
Article in Annals of the American Thoracic Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
rationaleAdvanced polysomnographic (PSG) metrics reflecting the physiological causes and consequences of sleep apnea may enable precision medicine in research settings, but their feasibility in routine clinical practice has yet to be demonstrated.
objectiveAssess (1) the generalizability of PSG metrics from research to clinical cohort and (2) their associations with a broad range of comorbid diseases, many of which have not been previously examined.
methodsPolysomnographic metrics, including endotypes (eg, loop gain) and physiological burdens (eg, hypoxic burden), were estimated from diagnostic polysomnographs of 6427 participants at Mass General Brigham (MGB). Comorbid conditions analyzed from MGB's medical record system included 9 representative cardiometabolic and respiratory diseases, as well as 408 prevalent diseases. Associations were assessed using modified Poisson and least absolute shrinkage and selection operator (LASSO) regression.
resultsThe sample included 62% females, aged 52.9 ± 16.8 years, and an apnea-hypopnea index (AHI) of 21.4 ± 15.9 events/h. Associations between endotypes and demographics/obesity-related factors were consistent with prior observational studies (median difference in β = 0.03 SD). After adjusting for AHI, older age was associated with lower heart rate (-0.40 SD) and arousal burdens (-0.23 SD), while higher body mass index was associated with increased hypoxic burden (0.25 SD). Having demonstrated reasonable concordance with published data, our subsequent analysis identified distinct and clinically meaningful associations between advanced PSG metrics and comorbid conditions. Specifically, elevated loop gain, ventilatory burden, and hypoxic burden were associated with hypertension, diabetes, and renal failure; increased ventilatory instability was associated with cardiovascular disease; and reduced collapsibility and ventilatory instability were associated with chronic airway obstruction. Even after LASSO-based selection, no single PSG metric consistently predicted risk across all comorbidities; ventilatory instability showed the most associations among endotypic traits and heart rate burden among physiological burdens, underscoring the heterogeneity of obstructive sleep apnea pathophysiology.
conclusionsPhenome-wide analyses of a large clinical cohort demonstrate the real-world feasibility and clinical relevance of extracting advanced PSG metrics, supporting their potential to identify personalized, mechanism-specific intervention targets for sleep apnea.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.